The Effect of Ipomoea batatas on Glycemic Control and Lipid Profiles in Animal Models: A Systematic Review and Meta‐Analysis Authors: Hapsari Sulistya Kusuma, Mohammad Sulchan, Heri-Nugroho H S, Suhartono Suhartono, Diana Nur Afifah, Endang Mahati, Arimi Fitri Mat Ludin, Adriyan Pramono, Munmun Bardhan Published: 2026 ABSTRACT AbstractBackgroundSweet potato (Ipomoea batatas), a fiber‐rich food with a low glycemic index, has shown potential in regulating glucose and lipid metabolism. This systematic review and meta‐analysis aimed to evaluate its effects on glycemic and lipid parameters in animal models of obesity and insulin resistance.MethodsRelevant experimental studies published in English were identified through PubMed, Scopus, Cochrane Library, and Embase, excluding in silico models. Data were extracted for fasting glucose, total cholesterol, triglycerides, low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C). Standardized mean differences (SMDs) with 95% confidence intervals were calculated, and risk of bias (RoB) was assessed using the SYRCLE RoB tool. The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD42025599301). The literature search was conducted from November 2024 to August 2025.ResultsTen studies involving 428 animals were included in the meta‐analysis. The meta‐analysis demonstrated that I. batatas administration significantly reduced fasting plasma glucose (SMD = −3.88; 95% CI: −5.63 to −2.13; p < 0.0001; I 2 = 87%) and improved lipid parameters, including reductions in total cholesterol, triglycerides, and LDL‐C and an increase in HDL‐C (SMD total cholesterol −21.5 [−38.49 to −4.55]; p = 0.01; I 2 = 93%; SMD triglycerides −4.83 [−9.07 to −0.60]; p = 0.03; I 2 = 93%; SMD LDL‐C −9.86 [−19.21 to −0.50]; p = 0.04; I 2 = 96%; SMD HDL‐C 11.13 [2.06 to 20.21]; p = 0.02; I 2 = 95%). These effects were observed for both leaf and root extracts.ConclusionSupplementation with I. batatas favorably influences fasting glucose and lipid profiles in animal models, suggesting its potential as a functional dietary component for improving metabolic health.Keywords: antioxidant, dietary fiber, dyslipidemia, experimental model, glycemic index, insulin resistance, sweet potato 1. Introduction The sweet potato (Ipomoea batatas) has potential implications for metabolic health, particularly in addressing insulin resistance. Insulin resistance is commonly associated with central obesity. The mechanism begins when adipose tissue stores lipids as triacylglycerols from chylomicron absorption and periodically releases nonesterified fatty acids to meet increasing energy demands. When energy intake exceeds expenditure, fatty acids accumulate beyond the adipose tissue storage capacity, leading to dysfunction. This dysfunction impairs insulin secretion, disrupting its role in inhibiting triacylglycerol extraction and endogenous lipolysis. As a result, insulin secretion increases, leading to higher circulating insulin levels. Without sufficient lipid buffering capacity, fatty acids enter the bloodstream and accumulate in the muscle, liver, and pancreas, contributing to insulin resistance [1]. Research on the effects of diets on insulin resistance in experimental animals and humans has been conducted; however, it has yielded less effective and practical results. A study by Utari et al. [2] indicated that low‐calorie and low‐glycemic index (GI) diets were less effective in reducing insulin resistance based on the HOMA‐IR index in obesity, due to the lack of proper intake monitoring. Despite this, a balanced, low‐calorie, and low‐glycemic dietary approach has been shown to result in significant weight loss, which is beneficial for treating obesity. Consequently, dietary therapy, especially with proper intake monitoring, remains a promising approach to manage insulin resistance, a common consequence of obesity. Current research focuses on identifying alternative staple food ingredients to replace rice. Foods high in fiber and low in GI are considered ideal for individuals at risk of insulin resistance. Based on this, I. batatas is a promising candidate due to its high fiber content, low GI of 46, and bioactive compounds like β‐carotene, which are absent in rice. Compared to rice (GI of 79.6), sweet potato has one‐third the calorie content, has 10 times more fiber, and contains β‐carotene, which has antidiabetic potential [3–5]. A review of the literature revealed limited in vivo and in vitro studies on I. batatas in relation to glycemic control and lipid profiles. Notably, Naomi et al. [6] focused primarily on diabetic retinopathy, examining retinal protection rather than systemic glycemic control or lipid profile modulation. Furthermore, this study did not specifically address Type 2 diabetes mellitus, limiting its applicability to the broader context of insulin resistance. Despite these limitations, there is no comprehensive synthesis addressing the effects of I. batatas on glycemic control and lipid profiles in animal models. Existing studies are heterogeneous in design and often focus on specific disease outcomes rather than broader metabolic parameters related to insulin resistance. Further investigation is needed to explore the impact of sweet potato intake on central obesity, particularly its effects on glycemic control and lipid regulation, which contribute to insulin resistance. Therefore, this study was designed to systematically review and meta‐analyze the effects of sweet potato on glycemic control and lipid profiles in animal models. This approach enables a comprehensive synthesis of the available evidence and is based on preliminary yet promising findings regarding its dietary effects ([7, 8]). 2. Methods 2.1. Overview of Reviews This systematic review and meta‐analysis (SR‐MA) followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 guidelines ([9]) and was prospectively registered in the PROSPERO database (CRD42025599301). The PRISMA 2020 checklist is provided in Supporting Information 2: File S1 and Supporting Information 3: File S2. 2.2. Search Strategy A comprehensive search was conducted across five databases: PubMed/MEDLINE, Scopus, Cochrane Library, EBSCO, and ProQuest. Studies published between January 1, 2000, and March 21, 2025, were included, using combinations of the terms “Ipomoea batatas,” “glycemic control,” “glucose homeostasis,” “lipid profile,” and “meta‐analysis.” Only intervention studies published in English and conducted using rodent models were included. Reference lists of eligible articles were screened to identify additional relevant studies. The search was conducted from November 2024 to August 2025. The same keyword strategy was applied across all databases using Boolean operators (“AND” and “OR”). The core search string was as follows: (“Ipomoea batatas” OR “sweet potato” OR “sweet potato extract”) AND (“type 2 diabetes” OR “blood glucose” OR “insulin resistance” OR “hyperglycemia” OR “glycemic control”) AND (“lipid metabolism” OR “lipid profile” OR “cholesterol” OR “triglycerides” OR “dyslipidemia”) AND (“animal study” OR “animal model” OR “in vivo” OR “rodent model” OR “experimental model”). The complete search strategy for PubMed is provided in Supporting Information 4: Table S1, in accordance with PRISMA 2020 recommendations. To minimize publication bias, additional gray literature searches were conducted in the WHO database, Universitas Diponegoro (UNDIP) institutional repository, and Indonesian Garuda database using the keywords “sweet potato,” “Ipomoea batatas,” “glucose,” “rats,” and “lipid.” No eligible records were identified in the WHO and UNDIP databases. Four records retrieved from the Garuda database were excluded because they did not meet the inclusion criteria. 2.3. Study Selection, Inclusion, and Exclusion Two reviewers independently screened titles and abstracts from the databases and additional sources to identify eligible studies. Interrater reliability was assessed using Cohen’s kappa coefficient, indicating moderate agreement (κ = 0.57). Articles were included if they met the following criteria: (1) randomized controlled animal studies evaluating I. batatas supplementation; (2) use of rat and/or mouse models representing obesity, metabolic syndrome, or Type 2 diabetes; and (3) measurable outcomes related to glycemic or lipid parameters. There were no restrictions regarding dose, frequency, or duration of I. batatas administration. Studies were excluded if they (1) were observational or noninterventional; (2) used in vitro, ex vivo, or in silico models; (3) involved animals receiving additional supplements unrelated to I. batatas; or (4) failed to report relevant glycemic or lipid outcomes. Full texts of shortlisted papers were independently reviewed by two authors, with disagreements resolved through discussion with a third reviewer. 2.4. Data Extraction and Synthesis Data extraction was performed independently by two authors using predesigned Microsoft Excel spreadsheets to ensure consistency and completeness. Discrepancies in extracted data were discussed and resolved by consensus. Extracted information included study design, intervention details, sample characteristics, and quantitative outcomes. If essential information was unavailable or unclear, no attempts were made to contact original study authors. For each included study, details were extracted on the publication reference, study design, animal characteristics (species, sex, and disease model), intervention description (form, dosage, and duration of I. batatas), comparator groups, and reported outcomes. Outcomes included fasting plasma glucose (FPG), oral glucose tolerance (2‐h OGTT), HOMA‐IR, and lipid measures (triglycerides, total cholesterol, low‐density lipoprotein cholesterol [LDL‐C], and high‐density lipoprotein cholesterol [HDL‐C]). Data expressed in nmol/L were standardized to mg/dL. All continuous variables were summarized as standardized mean differences (SMDs) with 95% confidence intervals. Key conclusions from the authors were also extracted to contextualize findings. The quality of each study was assessed, and effect sizes were interpreted using standard conventions: SMDs of > 0.8 (large), 0.5–0.8 (moderate), 0.2–0.5 (small), and < 0.2 (minimal). Potential overlap among studies was checked to ensure data independence. SR‐MAs were conducted using a random‐effects model to account for between‐study variability. Statistical heterogeneity was assessed using the I 2 statistic. Sensitivity analyses were performed using a leave‐one‐out approach to assess the robustness of the pooled estimates. Publication bias (small‐study effects) was assessed through visual inspection of funnel plots. Although 10 studies were included, formal statistical tests for funnel plot asymmetry (e.g., Egger’s regression test) were not performed due to limited reliability in meta‐analyses with a small number of studies. 2.5. Quality Assessment The methodological quality of included studies was assessed using the SYRCLE risk‐of‐bias (RoB) tool, specifically designed for animal intervention studies and adapted from the Cochrane RoB tool. The SYRCLE RoB tool includes 10 domains, covering potential sources of bias at different study stages, including selection, performance, detection, attrition, and reporting bias. The 10 domains assessed include the following: (1) sequence generation (randomization), (2) baseline characteristics, (3) allocation concealment, (4) random housing, (5) blinding of caregivers and/or investigators, (6) random outcome assessment, (7) blinding of outcome assessors, (8) incomplete outcome data, (9) selective outcome reporting, and (10) other sources of bias. Overall study quality was categorized as “good,” “fair,” or “poor,” based on the number of unmet quality criteria (0, 1, or ≥ 2, respectively). Assessments were performed independently by two reviewers. The original quality ratings from the included studies were documented for comparison. 3. Results and Discussion 3.1. Overview of Reviews A total of 435 records were initially identified through database searches. After removing duplicates, 413 unique articles remained. Screening titles and abstracts excluded 183 papers that did not meet the inclusion criteria. Sixty full‐text articles were assessed for eligibility, with 26 studies retained for qualitative synthesis. Ten original studies met all criteria and were included in the quantitative meta‐analysis (Figure 1 and Table 1). PRISMA flow diagram depicting the screening process for inclusion of studies in the qualitative synthesis. Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. Table 1Characteristics of included systematic reviews.ReferencePopulation characteristicsIntervention and comparisonOutcomesNumber of participants[10]HFD‐induced hyperglycemia, various doses of purple leaf NS: normal rats + normal salineDNS: diabetic rats + normal salineD25G: diabetic rats + gliclazide 25 mg/kgDT 200: diabetic rats + PSPL extract 200 mg/kgDT 400: diabetic rats + PSPL extract 400 mg/kg FBG, TAC/FRAP, IL‐17A50 (10/group)[11]T2DM mice (model induced), SPLP‐L and SPLP‐H groups NC: normal control groupDC: diabetic control groupMET: metformin 100 mg/kg BWSPLP‐L: low‐dose sweet potato leaf polyphenols (SPLP) (80 mg/kg BW)SPLP‐H: high‐dose SPLP (150 mg/kg BW)ETH‐L: low‐dose ethyl acetate extract (ETH) (10 mg/kg BW)ETH‐H: high‐dose ETH (30 mg/kg BW)KAE‐L: low‐dose kaempferol (KAE) (10 mg/kg BW)KAE‐H: high‐dose KAE (30 mg/kg BW) FBG, AUC, insulin90 (10/group)[12]Sprague‐Dawley rats, male, aged 2–3 months, 180–200 g body weight, Type 1 diabetes model induced by multiple low‐dose streptozotocin (STZ) injections (40 mg/kg BW) intraperitoneally for 5 consecutive days. Diabetes was confirmed when FBG was > 200 mg/dL IG1 (0.25 g/kg): Ipomoea batatas leaf extract (intervention group)IG2 (0.8 g/kg): Ipomoea batatas leaf extract (intervention group)IG3 (2.5 g/kg): Ipomoea batatas leaf extract (intervention group)NC (normal control): no treatmentDC (diabetic control): STZ‐induced diabetic rats (untreated)↓ FBG, ↓ insulitis severity, ↑ β‐cell insulin expression FBG, insulitis severity, β‐cell insulin expression25 (5/group)[13]STZ‐induced diabetic rats, treated with flavonoid extract NC: normal control groupDC: diabetic control groupDLF: diabetic + FIBL (50 mg/kg)DMF: diabetic + FIBL (100 mg/kg)DHF: diabetic + FIBL (150 mg/kg)DG: diabetic + glibenclamide (0.25 mg/kg) FBG, lipids, HDL60 (10/group)[14]Hypercholesterolemic rats by diet, 1% cholesterol E400: Ipomoea batatas leaf extract (400 mg/kg)E500: Ipomoea batatas leaf extract (500 mg/kg)E600: Ipomoea batatas leaf extract (600 mg/kg)NC: normocholesterolemic groupHC: hypercholesterolemic control group Lipids, histological improvement50 (10/group)[15]Wistar rats, fed high‐cholesterol diet Control group: high‐cholesterol diet without supplementationPSPE group: high‐cholesterol diet with purple sweet potato extract at 200 mg/day/rat TC, TG, LDL, MDA, HDL, SOD, Apo‐E, netrin‐120 (10/group)[16]Male mice (Mus musculus), aged 12–14 weeks, 25–30 g body weight, diabetes induced by a single intraperitoneal injection of STZ (60 mg/kg BW) plus a 10% dextrose diet to promote insulin resistance PSP‐CMC: purple sweet potato extract loaded with CMC‐alginate nanocapsules (0.5 mL)PSP: regular purple sweet potato extract (0.5 mL)POS: positive control (glibenclamide 0.39 mg/L, 1 mL)NEG: negative control (0.5% CMC sodium placebo) FBG24 (6/group)[17]KK‐Ay mice, spontaneous T2DM model, starting age 4 weeks CG (control group): no treatment, just fed normal dietSP (sweet potato leaf extract group): 300 mg/kg of leaf extract administered daily for 5 weeks FBG, insulin16 (8/group)[18]Male rats, cholesterol‐enriched diet induced hyperlipidemia CG: control groupPC Lam extract: 0.4 cc/rat/dayIB L tablet: 200 mg/rat/dayPC Lam extract + IB L tablet: 0.4 cc + 200 mg/rat/day TC, TG, LDL, HDL, MDA, SOD28 (7/group)[19]Male Kunming mice, 8 weeks old, 18–20 g, T2DM induced with HFD + STZ Control group (CG): standard diet + vehicleModel group (MG): HFD + STZ + vehicleLP group (LP): HFD + STZ + low‐dose PSPA (227.5 mg/kg BW)MP group (MP): HFD + STZ + medium‐dose PSPA (455 mg/kg BW)HP group (HP): HFD + STZ + high‐dose PSPA (910 mg/kg BW) FBG, HbA1c, GHB, TNF‐α, IL‐6, LPS, GSH‐PX65 (13/group) Characteristics of included systematic reviews. NS: normal rats + normal saline NS: normal rats + normal saline DNS: diabetic rats + normal saline DNS: diabetic rats + normal saline D25G: diabetic rats + gliclazide 25 mg/kg D25G: diabetic rats + gliclazide 25 mg/kg DT 200: diabetic rats + PSPL extract 200 mg/kg DT 200: diabetic rats + PSPL extract 200 mg/kg DT 400: diabetic rats + PSPL extract 400 mg/kg DT 400: diabetic rats + PSPL extract 400 mg/kg NC: normal control group NC: normal control group DC: diabetic control group DC: diabetic control group MET: metformin 100 mg/kg BW MET: metformin 100 mg/kg BW SPLP‐L: low‐dose sweet potato leaf polyphenols (SPLP) (80 mg/kg BW) SPLP‐L: low‐dose sweet potato leaf polyphenols (SPLP) (80 mg/kg BW) SPLP‐H: high‐dose SPLP (150 mg/kg BW) SPLP‐H: high‐dose SPLP (150 mg/kg BW) ETH‐L: low‐dose ethyl acetate extract (ETH) (10 mg/kg BW) ETH‐L: low‐dose ethyl acetate extract (ETH) (10 mg/kg BW) ETH‐H: high‐dose ETH (30 mg/kg BW) ETH‐H: high‐dose ETH (30 mg/kg BW) KAE‐L: low‐dose kaempferol (KAE) (10 mg/kg BW) KAE‐L: low‐dose kaempferol (KAE) (10 mg/kg BW) KAE‐H: high‐dose KAE (30 mg/kg BW) KAE‐H: high‐dose KAE (30 mg/kg BW) IG1 (0.25 g/kg): Ipomoea batatas leaf extract (intervention group) IG1 (0.25 g/kg): Ipomoea batatas leaf extract (intervention group) IG2 (0.8 g/kg): Ipomoea batatas leaf extract (intervention group) IG2 (0.8 g/kg): Ipomoea batatas leaf extract (intervention group) IG3 (2.5 g/kg): Ipomoea batatas leaf extract (intervention group) IG3 (2.5 g/kg): Ipomoea batatas leaf extract (intervention group) NC (normal control): no treatment NC (normal control): no treatment DC (diabetic control): STZ‐induced diabetic rats (untreated) DC (diabetic control): STZ‐induced diabetic rats (untreated) ↓ FBG, ↓ insulitis severity, ↑ β‐cell insulin expression ↓ FBG, ↓ insulitis severity, ↑ β‐cell insulin expression NC: normal control group NC: normal control group DC: diabetic control group DC: diabetic control group DLF: diabetic + FIBL (50 mg/kg) DLF: diabetic + FIBL (50 mg/kg) DMF: diabetic + FIBL (100 mg/kg) DMF: diabetic + FIBL (100 mg/kg) DHF: diabetic + FIBL (150 mg/kg) DHF: diabetic + FIBL (150 mg/kg) DG: diabetic + glibenclamide (0.25 mg/kg) DG: diabetic + glibenclamide (0.25 mg/kg) E400: Ipomoea batatas leaf extract (400 mg/kg) E400: Ipomoea batatas leaf extract (400 mg/kg) E500: Ipomoea batatas leaf extract (500 mg/kg) E500: Ipomoea batatas leaf extract (500 mg/kg) E600: Ipomoea batatas leaf extract (600 mg/kg) E600: Ipomoea batatas leaf extract (600 mg/kg) NC: normocholesterolemic group NC: normocholesterolemic group HC: hypercholesterolemic control group HC: hypercholesterolemic control group Control group: high‐cholesterol diet without supplementation Control group: high‐cholesterol diet without supplementation PSPE group: high‐cholesterol diet with purple sweet potato extract at 200 mg/day/rat PSPE group: high‐cholesterol diet with purple sweet potato extract at 200 mg/day/rat PSP‐CMC: purple sweet potato extract loaded with CMC‐alginate nanocapsules (0.5 mL) PSP‐CMC: purple sweet potato extract loaded with CMC‐alginate nanocapsules (0.5 mL) PSP: regular purple sweet potato extract (0.5 mL) PSP: regular purple sweet potato extract (0.5 mL) POS: positive control (glibenclamide 0.39 mg/L, 1 mL) POS: positive control (glibenclamide 0.39 mg/L, 1 mL) NEG: negative control (0.5% CMC sodium placebo) NEG: negative control (0.5% CMC sodium placebo) CG (control group): no treatment, just fed normal diet CG (control group): no treatment, just fed normal diet SP (sweet potato leaf extract group): 300 mg/kg of leaf extract administered daily for 5 weeks SP (sweet potato leaf extract group): 300 mg/kg of leaf extract administered daily for 5 weeks CG: control group CG: control group PC Lam extract: 0.4 cc/rat/day PC Lam extract: 0.4 cc/rat/day IB L tablet: 200 mg/rat/day IB L tablet: 200 mg/rat/day PC Lam extract + IB L tablet: 0.4 cc + 200 mg/rat/day PC Lam extract + IB L tablet: 0.4 cc + 200 mg/rat/day Control group (CG): standard diet + vehicle Control group (CG): standard diet + vehicle Model group (MG): HFD + STZ + vehicle Model group (MG): HFD + STZ + vehicle LP group (LP): HFD + STZ + low‐dose PSPA (227.5 mg/kg BW) LP group (LP): HFD + STZ + low‐dose PSPA (227.5 mg/kg BW) MP group (MP): HFD + STZ + medium‐dose PSPA (455 mg/kg BW) MP group (MP): HFD + STZ + medium‐dose PSPA (455 mg/kg BW) HP group (HP): HFD + STZ + high‐dose PSPA (910 mg/kg BW) HP group (HP): HFD + STZ + high‐dose PSPA (910 mg/kg BW) 3.2. Characteristics of Included Studies The studies included in the meta‐analysis are summarized in Table 1. The included studies spanned from 2015 to 2025, all of which were randomized controlled trials (n = 10). The intervention period for I. batatas administration ranged from 1 to 12 weeks. Six studies investigated leaf extracts, whereas four evaluated root extracts. All trials reported pre‐ and postintervention outcomes measured at the end of each treatment period. 3.3. Quality of Original Studies Included in the SR‐MA Based on SYRCLE criteria, one study was classified as “good” quality and nine as “fair.” None were rated as “poor.” All included studies clearly defined their research questions and eligibility criteria, applied systematic search strategies, and comprehensively reported study characteristics and findings. 3.4. Effectiveness of I. batatas 3.4.1. Glycemic Control Seven studies reported a significant decrease in fasting blood glucose (FBG) among animals receiving I. batatas compared to the control group, regardless of whether the extract was derived from leaves or roots. The SMD for FBG reduction was −3.88 [−5.63 to −2.13], with p < 0.0001 and I 2 = 87% (Figure 2). These decreases in blood glucose highlight effective glycemic control and prompt further investigation into the underlying mechanisms. Overview of reviews on the effect of Ipomoea batatas on fasting blood glucose. One mechanism involves the relatively low GI of I. batatas. Numerous studies have explored the role of I. batatas in regulating FBG, particularly in the context of diabetes. Research shows that sweet potatoes have a lower GI compared to other high‐carbohydrate foods, making them beneficial in managing Type 2 diabetes by reducing FBG spikes and the overall glycemic response [20–22]. In addition to their low GI, the dietary fiber in sweet potatoes plays a key role in maintaining glucose homeostasis. The dietary fiber in sweet potatoes contributes to lower FBG levels and improved glycemic control by delaying carbohydrate absorption. Evidence suggests that the combined benefits of low‐glycemic‐load meals and fiber improve FBG and other diabetes‐related indicators ([23], [21, 24]). Incorporating low‐GI foods, such as sweet potatoes, into daily meals can improve glycemic management, consistent with meta‐analysis findings showing a significant reduction in FPG among individuals following low‐GI diets [20–22]. Our meta‐analyses included studies on I. batatas in diverse forms, including both leaf and root extracts. Subgroup analyses indicated that both sweet potato leaf and root interventions significantly reduce FBG (Supporting Information 1: Figure S1). 3.4.2. Lipid Profiles Three of 10 studies reported significant decreases in total cholesterol, triglycerides, and LDL‐C, along with an increase in HDL‐C, in the I. batatas intervention group compared to the control group, regardless of whether the extract was derived from leaves or roots. The SMDs for lipid parameters were as follows: total cholesterol −21.5 [−38.49 to −4.55], p = 0.01; triglycerides −4.83 [−9.07 to −0.60], p = 0.03; LDL‐C −9.86 [−19.21 to −0.50], p = 0.04; HDL‐C 11.13 [2.06 to 20.21], p = 0.02 (Figures 3, 4, 5, and 6). Overview of reviews on the effect of Ipomoea batatas on total cholesterol. Overview of reviews on the effect of Ipomoea batatas on triglycerides. Overview of reviews on the effect of Ipomoea batatas on LDL‐C. Overview of reviews on the effect of Ipomoea batatas on HDL‐C. Although the pooled analysis showed statistically significant improvements in FPG levels and lipid parameters, the clinical significance of these findings must be interpreted cautiously. The use of SMDs limits direct clinical interpretation, as effect sizes are expressed in unitless values rather than conventional clinical measures (e.g., mg/dL). The high heterogeneity observed across studies (I 2 > 85%) indicates substantial variability in intervention type, dosage, duration, and animal models, which may have contributed to the variability in pooled effects. Therefore, these findings should be regarded as evidence of potential biological efficacy in animal models rather than direct therapeutic effects in humans. 3.5. Publication Bias Publication bias was assessed through visual inspection of funnel plots for each outcome, including FBG (Figure 7), total cholesterol (Figure 8), triglycerides (Figure 9), LDL‐C (Figure 10), and HDL‐C (Figure 11). The funnel plots appeared relatively symmetrical, suggesting no substantial evidence of publication bias among the included studies. However, these findings should be interpreted cautiously due to the limited number of studies for each outcome (≤ 10). Funnel plot of the effect of Ipomoea batatas on fasting blood glucose. Funnel plot of the effect of Ipomoea batatas on total cholesterol. Funnel plot of the effect of Ipomoea batatas on triglycerides. Funnel plot of the effect of Ipomoea batatas on LDL‐C. Funnel plot of the effect of Ipomoea batatas on HDL‐C. Interest in I. batatas has grown due to its potential impact on lipid profiles. The unique nutritional composition, including high dietary fiber, antioxidants, and other bioactive compounds, may positively influence lipid metabolism. The dietary fiber in I. batatas contributes to lower FBG levels and improved glycemic control by delaying carbohydrate absorption. Evidence suggests that the combined benefits of low‐glycemic‐load meals and fiber improve FBG and other diabetes‐related indicators [25, 26]. The antioxidant activity in I. batatas roots may help reduce oxidative stress, which is associated with lipid profile deterioration and cardiovascular risk factors. Studies suggest that regular consumption of antioxidant‐rich foods can reduce triglycerides and increase HDL‐C levels [27, 28]. Sweet potatoes, with their relatively low GI, raise blood sugar levels gradually and may improve lipid metabolism by enhancing insulin sensitivity. Since insulin regulates lipid synthesis and breakdown, increased insulin sensitivity is often associated with improved lipid profiles [27, 29]. This relationship underscores the importance of incorporating low‐glycemic foods, such as sweet potatoes, in managing metabolic syndrome and dyslipidemia to improve cardiovascular health. Additionally, I. batatas contains specific phytochemicals, such as anthocyanins and phenolic compounds, which may benefit lipid metabolism by modulating enzymes involved in lipid production and transport [28]. These findings align with the broader framework of dietary patterns, where consumption of fruits, vegetables, and whole grains has been shown to alter lipid profiles through various biochemical pathways [25, 26]. The findings of this review are broadly consistent with those reported by Naomi et al. [6], who described I. batatas as a versatile plant with potential therapeutic relevance. In their study, I. batatas administration was associated with improvements in hyperglycemia, with effects greater than those observed for Diabinese, a commonly used antidiabetic agent. After 8 weeks of intervention, improvements in pancreatic β‐cell function, reductions in lipid levels, attenuation of insulin resistance, and a lower GI were observed [6]. Although the underlying mechanisms are biologically plausible, the clinical significance of the observed effect sizes remains uncertain. While the pooled analyses demonstrated statistically significant improvements in fasting glucose and lipid parameters, the magnitude of these effects appears modest when compared to commonly used clinical thresholds and established therapeutic interventions. Likewise, although the lipid profile changes were generally favorable, their clinical relevance depends on baseline dyslipidemia severity, the durability of effects over time, and their translatability from preclinical models to humans. Given that all included studies were conducted exclusively in rat models, these findings should primarily be interpreted as evidence of potential biological efficacy, warranting further confirmation in well‐designed human studies with adequate statistical power and clinically interpretable endpoints. 4. Conclusion Supplementation with I. batatas was associated with reductions in FBG and improvements in lipid parameters in rat models of metabolic disturbance. These findings suggest potential biological effects, but they should be regarded with caution, as clinical therapeutic effects remain unconfirmed. The mechanisms behind these effects are likely related to the low GI, high fiber content, and bioactive compounds in I. batatas, which may counteract the effects of high‐glycemic foods and improve dyslipidemia. However, the magnitude of these effects appears modest, and their clinical relevance in humans remains uncertain due to substantial heterogeneity and the use of standardized effect measures. Future well‐designed, adequately powered randomized controlled trials in human populations are needed to determine whether these changes translate into clinically meaningful reductions in cardiometabolic risk and improvements in cardiovascular health. 5. Limitations The number of articles meeting the inclusion criteria in this meta‐analysis was limited (n = 10), potentially affecting the statistical power of the analysis. There was considerable heterogeneity across studies, reflected by variations in animal models, intervention types, dosages, and treatment durations, which may have contributed to the variability in pooled effects. All included studies were conducted in animal models, limiting the generalizability of the findings to human populations. Therefore, these results should be regarded as evidence of the potential biological effects of I. batatas in experimental models, not as direct therapeutic effects in humans. Despite these limitations, this meta‐analysis demonstrated an association between I. batatas administration and significant improvements in glycemic and lipid parameters. Future research should include more studies and well‐designed controlled clinical trials in humans to improve the generalizability of the findings and strengthen clinical evidence regarding the effects of I. batatas on metabolic parameters. Author Contributions Hapsari Sulistya Kusuma, Mohammad Sulchan, Heri‐Nugroho H.S., Suhartono Suhartono, Diana Nur Afifah, Endang Mahati, Arimi Fitri Mat Ludin, and Adriyan Pramono conceptualized the study. Hapsari Sulistya Kusuma and Adriyan Pramono performed keyword screening, data extraction, and meta‐analysis. All authors participated in data interpretation. Hapsari Sulistya Kusuma and Adriyan Pramono drafted the manuscript, with critical revisions by all authors. Funding This work was supported by Universitas Diponegoro (grant number 222‐234/UN7.D2/PP/IV/2025). Conflicts of Interest All authors declare no competing interests. The corresponding author is supported by Universitas Diponegoro; however, the agency was not involved in the conceptualization, writing, or submission of the manuscript. Supporting Information Additional supporting information can be found online in the Supporting Information section. Supporting information Supporting Information 1 Figure S1: Subanalysis on the effect of Ipomoea batatas leaves and roots on fasting blood glucose. Supporting Information 2 File S1: PRISMA 2020 checklist. Supporting Information 3 File S2: PRISMA 2020 abstract checklist. Supporting Information 4 Table S1: Full electronic search strategy for PubMed. Acknowledgments All authors thank the Faculty of Medicine, Universitas Diponegoro, for their support. The first author would like to express sincere gratitude to the Indonesian Education Scholarship (Beasiswa Pendidikan Indonesia), administered by the Center for Higher Education Funding and Assessment under the Ministry of Higher Education, Science, and Technology of the Republic of Indonesia, as well as the Indonesian Endowment Fund for Education, for the financial support provided. Kusuma, Hapsari Sulistya , Sulchan, Mohammad , H. S., Heri‐Nugroho , Suhartono, Suhartono , Afifah, Diana Nur , Mahati, Endang , Ludin, Arimi Fitri Mat , Pramono, Adriyan , The Effect of Ipomoea batatas on Glycemic Control and Lipid Profiles in Animal Models: A Systematic Review and Meta‐Analysis, International Journal of Food Science, 2026, 1713161, 11 pages, 2026. 10.1155/ijfo/1713161 Academic Editor: Munmun Bardhan Contributor Information Adriyan Pramono, Email: adriyanpramono@fk.undip.ac.id. Munmun Bardhan, Email: mbardhan@wiley.com. Data Availability Statement The data supporting the findings of this study are available in the references within the article. References Associated Data Supplementary Materials Supporting Information 1 Figure S1: Subanalysis on the effect of Ipomoea batatas leaves and roots on fasting blood glucose. Supporting Information 2 File S1: PRISMA 2020 checklist. Supporting Information 3 File S2: PRISMA 2020 abstract checklist. Supporting Information 4 Table S1: Full electronic search strategy for PubMed. Data Availability Statement The data supporting the findings of this study are available in the references within the article.